Inlexisertib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the serine/threonine-protein kinase ULK 1 and 2, with potential antineoplastic activity. Upon oral administration, inlexisertib targets and binds to ULK1/2. This inhibits cancer autophagy, which mutant RAS cancer cells use for their survival, and results in tumor cell death. ULK1/2 mediates the autophagocytotic process and is often upregulated in cancers, especially in mutant RAS cancers. Autophagy plays a key role in a tumor cell proliferation and survival, and mediates tumor cell resistance.

**Synonyms:** - DCC 3116 - DCC 3116 Free Base - DCC-3116 - DCC-3116 Free Base - DCC3116 - DCC3116 Free Base - INLEXISERTIB - ULK1/2 Inhibitor DCC-3116